<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000017/abos-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000017/0001576885-23-000017-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Acumen Pharmaceuticals Inc

Part One: Analysis of Performance
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a sole focus on developing immunotherapy drug candidate ACU193, which is intended to treat Alzheimer's disease (AD). The drug came into the spotlight after gaining scientific acceptance as a primary toxin involved in the initiation and propagation of the AD pathology. The company's strategic shift to develop ACU193 has attracted significant investors, raising a total of $168.6 million in its IPO. ACU193 is currently at clinical proof-of-mechanism trial in early AD patients. The trial is focused on testing the drug's safety, efficacy and tolerability as well as establishing clinical proof-of-mechanism by clinically assessing the presence or absence of amyloid-related imaging abnormalities (ARIA) using MRI. 
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and has generated significant investment capital since 2018 from sales of preferred stock, sales of common stock and issuance of notes that were converted to preferred stock. It funded its operations through these sources as it has not generated any revenue from product sales. The company recorded net losses and negative cash flows from operations since its inception, with research and development spending accounting for the bulk of the losses. As a clinical-stage biopharmaceutical company, expenses and operating losses are expected to increase as the company continues to advance ACU193 in clinical trials, seek to expand its portfolio and grow its clinical, regulatory and quality capabilities. Its net losses and cash flows may fluctuate extensively based on the timing of its research and development activities.

Part Two: Future Outlook
The development of ACU193, the company's flagship immunotherapy candidate drug, has the potential to be a game-changer in AD treatment, and future successful clinical trials on the drug will boost investor confidence. The INTERCEPT-AD trial is the company's initial Phase I clinical trial on ACU193, and it represents a significant milestone for the company. Any successful outcome from the clinical trial could create enormous value for Acumen Pharmaceuticals, Inc., and its investors. The Alzheimer's treatment market is extremely competitive, with numerous established players as well as innovative drug developers vying for a share of the market. The market size is large and growing, indicating numerous opportunities for drug developers. Management believes that its immunotherapy drug candidate has a competitive edge over other AD drugs because it targets the underlying cause of AD. The company will likely continue to seek third-party collaboration for future commercialization of ACU193 or any other product candidate it develops if it secures regulatory approvals. Although Acumen Pharmaceuticals, Inc. has generated negative cash flows and has incurred net losses since its inception, it has the prospect of becoming profitable in the future. Investors should continue to monitor the company's progress in developing its pipeline and look out for clinical trial results that could significantly impact its future performance.

Acumen Pharma's ACU193: Promising Alzheimer's Drug Candidate Analysis

Announcement: ABOS 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/abos-20230327.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000013/0001576885-23-000013-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 7.01 Item 9.01

Acumen Pharmaceuticals, Inc. has just released its 2022 financial results and announced a cash balance of $193.4 million as of December 31, 2022. In addition, the company shared a business update, highlighting the ongoing development of ACU193, a drug for treating Alzheimer's disease (AD). Acumen Pharmaceuticals expects to report the Phase 1 topline results for ACU193 in Q3 2023 and anticipates FDA interaction in Q4 2023. CEO Mark Connell says, "Our efforts in 2022 have allowed us to maintain strong momentum during 2023." 

ACU193 was granted Fast Track designation in October 2022 and targets the primary underlying cause of the neurodegenerative process in AD. In addition, Acumen Pharmaceuticals expanded its team, appointing Liean Schenck as VP of Chemistry, Manufacturing, and Controls and Derek Meisner as Chief Legal Officer. 

Despite reporting a net loss of $42.1 million for 2021, the company remains optimistic about ACU193. However, continued success and regulatory approval cannot be guaranteed. Acumen Pharmaceuticals will hold a conference call and live audio webcast on March 27, 2023, at 8:00 a.m. ET to discuss the results and business update.

$ABOS reports Acumen Pharma's $193M cash balance and ACU193 drug update.

Announcement: ABOS 8-K Special Filing

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000008/abos-20230309.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000157688523000008/0001576885-23-000008-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 5.03 Item 9.01

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1494695/000183988223003759/abos-sc13ga_123122.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000183988223003759/0001839882-23-003759-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ABOS SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000117570723000085/13ga1_acumen.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000117570723000085/0001175707-23-000085-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000117266123000812/deeptrack-abos123122a1.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1576885/000117266123000812/0001172661-23-000812-index.htm>Original filing index</a>
                    </div>